Summary:

Despite pricing pressure, regulatory obstacles, and geopolitical unpredictability, India's pharmaceutical exports shown remarkable resiliency in FY26, surpassing Rs. 2.86 lakh crore (US$31 billion). The expansion demonstrates India's standing as a top worldwide provider of reasonably priced medications, bolstered by a strong manufacturing base and a wide range of export markets. Generics, bulk medications, vaccines, and biosimilars are important markets with demand from the US, Europe, Africa, and developing nations. The industry has been boosted by government programs like the Production Linked Incentive scheme and a greater emphasis on research, innovation, and sophisticated medicines. Growing expenditures on biotechnology and specialized medications are anticipated to increase exports and improve India's competitiveness in the global pharmaceutical market.

Source: IBEF

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.